Factors affecting circuit patency and filter 'life'

Contributions to Nephrology

Volumn 156, Issue , 2007, Pages 178-184

  Baldwin, Ian ^a,b  

^a AUSTIN HOSPITAL   (Australia)

^b RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; BLOOD CLOTTING; BLOOD FLOW; DRUG EFFECT; EDUCATION; EQUIPMENT; EXTRACORPOREAL CIRCULATION; HUMAN; INDWELLING CATHETER; INSTRUMENTATION; KIDNEY; METHODOLOGY; NURSING STAFF; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; VASCULAR PATENCY; VASCULARIZATION;

ANTICOAGULANTS; BLOOD COAGULATION; CATHETERS, INDWELLING; EQUIPMENT FAILURE; EXTRACORPOREAL CIRCULATION; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; NURSING STAFF; REGIONAL BLOOD FLOW; RENAL REPLACEMENT THERAPY; VASCULAR PATENCY;

EID: 34247585788     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/0000102081     Document Type: Article

References (25)

1. Davenport A: The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis 1997;30(suppl 4):s20-s27.
2. Keller F, Seeman J, Preuschof L, Offermann G: Risk factors of system clotting in heparin free hemodialysis. Nephrol Dial Transplant 1990;5:802-807.
3. Oudemans-Van Straaten HM, Wester JPJ, de Pont ACJM, Schetz MRC: Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based ? Intensive Care Med 2006;32:188-202.
4. Baldwin I, Bellomo R: The relationship between blood flow, access catheter and circuit failure during CRRT; a practical review; in Ronco C, Bellomo R, Brendolan A (eds): Sepsis, Kidney and Multiple Organ Failure. Contrib Nephrol. Basel, Karger, 2004, vol 144, pp 203-213.
5. Webb AR, Mythen, MG, Jacobsen D, Mackie IJ: Maintaining blood flow in the extracorporeal circuit: hemostasis and anticoagulation. Intensive Care Med 1995;21:84-93.
6. Bellomo R, Ronco C: Circulation of the continuous artificial kidney: blood flow, pressures, clearance and the search for the best; in Artigas A, Bellomo R, Ronco C (eds): Circulation in Native and Artificial Kidneys. Karger, Basel, 1997, pp 138-149.
7. Mitchell A, Daul AE, Beiderlinden M, Schafers RF, Heemann U, Kribben A, et al: A new system for regional citrate anticoagulation in continuous veno-venous hemodialysis (CVVHD). Clin Nephrol 2003;59:106-114.
8. Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT: Regional citrate anticoagulation in continuous veno-venous hemodiafiltration. Am J Kidney Dis 2000;35:802-811.
9. Schetz M: Anticoagulation for continuous renal replacement therapy. Curr Opin Anaesthesiol 2001;14 143-149.
10. Baldwin IC, Elderkin TD: CVVH in intensive care. Nursing perspectives. New Horiz 1995;3:738-747.
11. Baldwin IC, Bridge NP, Elderkin TD: Nursing issues, practices, and perspectives for the management of continuous renal replacement therapy in the intensive care unit; in Bellomo R, Ronco C (eds): Critical Care Nephrology. Dordrecht, Kluwer Academic, 1998, pp 1309-1327.
12. Davenport A: Extracorporeal anticoagulation for intermittent and continuous forms of renal replacement therapy in the intensive care unit; in Murray PT, Brady HR, Hall JB (eds): Intensive Care Nephrology. London, Taylor & Francis, 2006, pp 165-180.
13. Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet J M, Renaux JL, Chanard J: Optimal anticoagulation strategy in haemodialysis with heparin coated polyacrylonitrile membrane. Nephrol Dial Transplant 2003;18:2097-2094.
14. Lavaud S, Paris B, Maheut H, Randoux C, Renaux JL, Rieu P, Chanard J: Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J 2005;51:348-351.
15. Jones CH: Continuous renal replacement therapy in acute renal failure: membranes for CRRT. Artif Organs 1998;22:2-7.
16. Salmon J, Cardigan R, Mackie I, Cohen SL, Machin S, Singer M: Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med 1997;23:38-43.
17. Frank RD, Weber J, Dresbach H, Thelan H, Weiss C, Floeg J: Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int 2001;60:1972-1981.
18. Hadef S, Raoudha G, Saoussen A, Imen K, Henda E, Jalel G, Abdelaziz H: A prospective study of the prevalence of heparin-induced antibodies and other associated thromboembolic risk factors in pediatric patients undergoing hemodialysis. Am J Hematol 2006;81:328-334.
19. Jenkins RD: The extra-corporeal circuit: physical principles and monitoring; in Ronco C, Bellomo R (eds): Critical Care Nephrology, ed 1. Dordrecht, Kluwer Academic, 1998, pp 1189-1197.
20. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract 2003;94:94-98.
21. Egi M, Naka T, Bellomo R, Cole L, French C, Trethewy C, Wan L, Langenberg CC, Fealy N, Baldwin I: A comparison of two citrate anticoagulation regimens for continuous veno-venous hemofiltration. J Artif Organs 2005;28:1211-1218.
22. Keller F, Seeman J, Preuschof L, Offermann G: Risk factors of system clotting in heparin free hemodialysis. Nephrol Dial Transplant 1990;5:802-807.
23. Baldwin I, Tan HK, Bridge N, Bellomo R: Possible strategies to prolong circuit life during hemofiltration: three controlled studies. Ren Fail 2002;24:839-848.
24. Ronco C: Fluid balance in CRRT: a call to attention! Int J Artif Organs 2005;28:763-764.
25. Baldwin I: Training management and credentialing for CRRT in critical care. Am J Kidney Dis 1997;30(suppl 4):S112-S116.